{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:25:32Z","timestamp":1788294332671,"version":"build-2803163510"},"reference-count":134,"publisher":"Japan Atherosclerosis Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2024,11,1]]},"DOI":"10.5551\/jat.rv22025","type":"journal-article","created":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T22:25:30Z","timestamp":1724279130000},"page":"1496-1511","source":"Crossref","is-referenced-by-count":16,"title":["Fibroblast Growth Factors in Cardiovascular Disease"],"prefix":"10.5551","volume":"31","author":[{"given":"Hideaki","family":"Morita","sequence":"first","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Hoshiga","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fern\u00e1ndez-Sol\u00e0 J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundstr\u00f6m J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, and Fuster V: Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol, 2020; 76: 2982-3021","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, and Ornitz DM: Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family. J Biol Chem, 2006; 281: 15694-15700","DOI":"10.1074\/jbc.M601252200"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ornitz DM and Itoh N: The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol, 2015; 4: 215-266","DOI":"10.1002\/wdev.176"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Beenken A and Mohammadi M: The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov, 2009; 8: 235-253","DOI":"10.1038\/nrd2792"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Beenken A and Mohammadi M: The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov, 2009; 8: 235-253","DOI":"10.1038\/nrd2792"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Farooq M, Khan AW, Kim MS, and Choi S: The role of fibroblast growth factor (FGF) signaling in tissue repair and regeneration. Cells, 2021; 10: 3242","DOI":"10.3390\/cells10113242"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Feldman B, Poueymirou W, Papaioannou VE, DeChiara TM, and Goldfarb M: Requirement of FGF-4 for postimplantation mouse development. Science, 1995; 267: 246-249","DOI":"10.1126\/science.7809630"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) H\u00e9bert JM, Rosenquist T, G\u00f6tz J, and Martin GR: FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations. Cell, 1994; 78: 1017-1025","DOI":"10.1016\/0092-8674(94)90276-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Armand AS, Laziz I, and Chanoine C: FGF6 in myogenesis. Biochim Biophys Acta, 2006; 1763: 773-778","DOI":"10.1016\/j.bbamcr.2006.06.005"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Tekin M, Hi\u015fmi BO, Fitoz S, Ozda\u011f H, Cengiz FB, Sirmaci A, Aslan I, Inceo\u011flu B, Y\u00fcksel-Konuk EB, Yilmaz ST, Yasun O, and Akar N: Homozygous mutations in fibroblast growth factor 3 are associated with a new form of syndromic deafness characterized by inner ear agenesis, microtia, and microdontia. Am J Hum Genet, 2007; 80: 338-344","DOI":"10.1086\/510920"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Qiao J, Uzzo R, Obara-Ishihara T, Degenstein L, Fuchs E, and Herzlinger D: FGF-7 modulates ureteric bud growth and nephron number in the developing kidney. Development, 1999; 126: 547-554","DOI":"10.1242\/dev.126.3.547"},{"key":"12","unstructured":"12) Kato S and Sekine K: FGF-FGFR signaling in vertebrate organogenesis. Cell Mol Biol (Noisy-Le-Grand), 1999; 45: 631-638"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Umemori H, Linhoff MW, Ornitz DM, and Sanes JR: FGF22 and its close relatives are presynaptic organizing molecules in the mammalian brain. Cell, 2004; 118: 257-270","DOI":"10.1016\/j.cell.2004.06.025"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Liu A and Joyner AL: Early anterior\/posterior patterning of the midbrain and cerebellum. Annu Rev Neurosci, 2001; 24: 869-896","DOI":"10.1146\/annurev.neuro.24.1.869"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Xu J, Liu Z, and Ornitz DM: Temporal and spatial gradients of Fgf8 and Fgf17 regulate proliferation and differentiation of midline cerebellar structures. Development, 2000; 127: 1833-1843","DOI":"10.1242\/dev.127.9.1833"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Liu Z, Xu J, Colvin JS, and Ornitz DM: Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev, 2002; 16: 859-869","DOI":"10.1101\/gad.965602"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Colvin JS, Green RP, Schmahl J, Capel B, and Ornitz DM: Male-to-female sex reversal in mice lacking fibroblast growth factor 9. Cell, 2001; 104: 875-889","DOI":"10.1016\/S0092-8674(01)00284-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Lu SY, Sheikh F, Sheppard PC, Fresnoza A, Duckworth ML, Detillieux KA, and Cattini PA: FGF-16 is required for embryonic heart development. Biochem Biophys Res Commun, 2008; 373: 270-274","DOI":"10.1016\/j.bbrc.2008.06.029"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Ohmachi S, Mikami T, Konishi M, Miyake A, and Itoh N: Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c. J Neurosci Res, 2003; 72: 436-443","DOI":"10.1002\/jnr.10592"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Armelin HA: Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc Natl Acad Sci U S A, 1973; 70: 2702-2706","DOI":"10.1073\/pnas.70.9.2702"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Gospodarowicz D: Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature, 1974; 249: 123-127","DOI":"10.1038\/249123a0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Caron A, Michelet S, Caron A, Sordello S, Ivanov MA, Dela\u00e8re P, Branellec D, Schwartz B, and Emmanuel F: Human FGF-1 gene transfer promotes the formation of collateral vessels and arterioles in ischemic muscles of hypercholesterolemic hamsters. J Gene Med, 2004; 6: 1033-1045","DOI":"10.1002\/jgm.594"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Schumacher B, Pecher P, von Specht BU, and Stegmann T: Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation, 1998; 97: 645-650","DOI":"10.1161\/01.CIR.97.7.645"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Pecher P and Schumacher BA: Angiogenesis in ischemic human myocardium: clinical results after 3 years. Ann Thorac Surg, 2000; 69: 1414-1419","DOI":"10.1016\/S0003-4975(00)01162-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, Sequeira R, Kent CK, Bacchetta M, Goldman C, Salenius JP, Schmieder FA, and Pilsudski R: Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg, 2002; 35: 930-936","DOI":"10.1067\/mva.2002.123677"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Nikol S, Baumgartner I, Van Belle E, Diehm C, Vison\u00e1 A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, and Meyer F: Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther, 2008; 16: 972-978","DOI":"10.1038\/mt.2008.33"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, and Van Belle E: Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet, 2011; 377: 1929-1937","DOI":"10.1016\/S0140-6736(11)60394-2"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ware JA and Simons M: Angiogenesis in ischemic heart disease. Nat Med, 1997; 3: 158-164","DOI":"10.1038\/nm0297-158"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Scholz D, Cai WJ, and Schaper W: Arteriogenesis, a new concept of vascular adaptation in occlusive disease. Angiogenesis, 2001; 4: 247-257","DOI":"10.1023\/A:1016094004084"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon III RO, and Quyyumi AA: Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol, 2000; 85: 1414-1419","DOI":"10.1016\/S0002-9149(00)00787-6"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, and Chronos NA: Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation, 2002; 105: 788-793","DOI":"10.1161\/hc0802.104407"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M, and Sellke FW: Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg, 2002; 124: 28-34","DOI":"10.1067\/mtc.2002.121974"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Lazarous DF, Unger EF, Epstein SE, Stine A, Arevalo JL, Chew EY, and Quyyumi AA: Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol, 2000; 36: 1239-1244","DOI":"10.1016\/S0735-1097(00)00882-2"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, and Annex BH: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet, 2002; 359: 2053-2058","DOI":"10.1016\/S0140-6736(02)08937-7"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Taira M, Yoshida T, Miyagawa K, Sakamoto H, Terada M, and Sugimura T: cDNA sequence of human transforming gene hst and identification of the coding sequence required for transforming activity. Proc Natl Acad Sci U S A, 1987; 84: 2980-2984","DOI":"10.1073\/pnas.84.9.2980"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, and Engler RL: Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation, 2002; 105: 1291-1297","DOI":"10.1161\/hc1102.105595"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, Kleiman N, and Angiogenic GENe Therapy (AGENT-2) Study Group: A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol, 2003; 42: 1339-1347","DOI":"10.1016\/S0735-1097(03)00988-4"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Henry TD, Grines CL, Watkins MW, Dib N, Barbeau G, Moreadith R, Andrasfay T, and Engler RL: Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol, 2007; 50: 1038-1046","DOI":"10.1016\/j.jacc.2007.06.010"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Kaski JC and Consuegra-Sanchez L: Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. Expert Opin Biol Ther, 2013; 13: 1749-1753","DOI":"10.1517\/14712598.2013.827656"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, Goelman G, and Keshet E: Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J, 2002; 21: 1939-1947","DOI":"10.1093\/emboj\/21.8.1939"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Dolegowska K, Marchelek-Mysliwiec M, Nowosiad-Magda M, Slawinski M, and Dolegowska B: FGF19 subfamily members: FGF19 and FGF21. J Physiol Biochem, 2019; 75: 229-240","DOI":"10.1007\/s13105-019-00675-7"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Walters JRF: Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol, 2014; 11: 426-434","DOI":"10.1038\/nrgastro.2014.32"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, and Kliewer SA: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab, 2005; 2: 217-225","DOI":"10.1016\/j.cmet.2005.09.001"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, and Mangelsdorf DJ: FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science, 2011; 331: 1621-1624","DOI":"10.1126\/science.1198363"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Zhou M, Learned RM, Rossi SJ, Tian H, DePaoli AM, and Ling L: Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. J Lipid Res, 2019; 60: 550-565","DOI":"10.1194\/jlr.M089961"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Wong YK, Cheung CYY, Tang CS, Au KW, Hai JSH, Lee CH, Lau KK, Cheung BMY, Sham PC, Xu A, Lam KSL, and Tse HF: Age-biomarkers-clinical risk factors for prediction of cardiovascular events in patients with coronary artery disease. Arterioscler Thromb Vasc Biol, 2018; 38: 2519-2527","DOI":"10.1161\/ATVBAHA.118.311726"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Xu W, Wang Y, Guo Y, Liu J, Ma L, Cao W, Yu B, and Zhou Y: Fibroblast growth factor 19 improves cardiac function and mitochondrial energy homoeostasis in the diabetic heart. Biochem Biophys Res Commun, 2018; 505: 242-248","DOI":"10.1016\/j.bbrc.2018.09.046"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Rinella ME: Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015; 313: 2263-2273","DOI":"10.1001\/jama.2015.5370"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, and Loomba R: NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2018; 391: 1174-1185","DOI":"10.1016\/S0140-6736(18)30474-4"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Harrison SA, Abdelmalek MF, Neff G, Gunn N, Guy CD, Alkhouri N, Bashir MR, Freilich B, Kohli A, Khazanchi A, Sheikh MY, Leibowitz M, Rinella ME, Siddiqui MS, Kipnes M, Moussa SE, Younes ZH, Bansal M, Baum SJ, Borg B, Ruane PJ, Thuluvath PJ, Gottwald M, Khan M, Chen C, Melchor-Khan L, Chang W, DePaoli AM, Ling L, and Lieu HD: Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol, 2022; 7: 603-616","DOI":"10.1016\/S2468-1253(22)00017-6"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Madan S, Mehra MR: The heart-gut microbiome axis in advanced heart failure. J Heart Lung Transplant, 2020; 39: 891-893","DOI":"10.1016\/j.healun.2020.04.003"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Vasavan T, Ferraro E, Ibrahim E, Dixon P, Gorelik J, and Williamson C: Heart and bile acids - clinical consequences of altered bile acid metabolism. Biochim Biophys Acta Mol Basis Dis, 2018; 1864: 1345-1355","DOI":"10.1016\/j.bbadis.2017.12.039"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Mor\u00f3n-Ros S, Blasco-Roset A, Navarro-Gascon A, Rup\u00e9rez C, Zamora M, Crispi F, Uriarte I, Fern\u00e1ndez-Barrena MG, Avila M, Ferrer-Curriu G, Lup\u00f3n J, Bay\u00e9s-Genis A, Villarroya F, Gavald\u00e0-Navarro A, and Planavila A: A new FGF15\/19-mediated gut-to-heart axis controls cardiac hypertrophy. J Pathol, 2023; 261: 335-348","DOI":"10.1002\/path.6193"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Nishimura T, Nakatake Y, Konishi M, and Itoh N: Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta, 2000; 1492: 203-206","DOI":"10.1016\/S0167-4781(00)00067-1"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, and Shanafelt AB: FGF-21 as a novel metabolic regulator. J Clin Invest, 2005; 115: 1627-1635","DOI":"10.1172\/JCI23606"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, and Kharitonenkov A: Fibroblast growth factor 21 corrects obesity in mice. Endocrinology, 2008; 149: 6018-6027","DOI":"10.1210\/en.2008-0816"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Wente W, Efanov AM, Brenner M, Kharitonenkov A, K\u00f6ster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, and Gromada J: Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways. Diabetes, 2006; 55: 2470-2478","DOI":"10.2337\/db05-1435"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, and Etgen GJ: The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 2007; 148: 774-781","DOI":"10.1210\/en.2006-1168"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Adams AC, Yang C, Coskun T, Cheng CC, Gimeno RE, Luo Y, and Kharitonenkov A: The breadth of FGF21\u2019s metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab, 2012; 2: 31-37","DOI":"10.1016\/j.molmet.2012.08.007"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ, Kliewer SA: \u03b2Klotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab, 2012; 16: 387-393","DOI":"10.1016\/j.cmet.2012.08.002"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, Shanafelt AB, Kharitonenkov A, and Wasserman DH: Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology, 2009; 150: 4084-4093","DOI":"10.1210\/en.2009-0221"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Fisher FM and Maratos-Flier E: Understanding the physiology of FGF21. Annu Rev Physiol, 2016; 78: 223-241","DOI":"10.1146\/annurev-physiol-021115-105339"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Hughes SE: Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem, 1997; 45: 1005-1019","DOI":"10.1177\/002215549704500710"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, Itoh N, Wang Y, Bornstein SR, Xu A, and Li X: Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab, 2013; 17: 779-789","DOI":"10.1016\/j.cmet.2013.04.005"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, Gabrielli LA, Sitges M, Giralt M, van Bilsen M, and Villarroya F: Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun, 2013; 4: 2019","DOI":"10.1038\/ncomms3019"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Li S, Zhu Z, Xue M, Yi X, Liang J, Niu C, Chen G, Shen Y, Zhang H, Zheng J, Zhao C, Liang Y, Cong W, Wang Y, and Jin L: Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1. Biochim Biophys Acta Mol Basis Dis, 2019; 1865: 1241-1252","DOI":"10.1016\/j.bbadis.2019.01.019"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Liu SQ, Roberts D, Kharitonenkov A, Zhang B, Hanson SM, Li YC, Zhang LQ, and Wu YH: Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep, 2013; 3: 2767","DOI":"10.1038\/srep02767"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Joki Y, Ohashi K, Yuasa D, Shibata R, Ito M, Matsuo K, Kambara T, Uemura Y, Hayakawa S, Hiramatsu-Ito M, Kanemura N, Ogawa H, Daida H, Murohara T, and Ouchi N: FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun, 2015; 459: 124-130","DOI":"10.1016\/j.bbrc.2015.02.081"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Kokkinos J, Tang S, Rye KA, and Ong KL: The role of fibroblast growth factor 21 in atherosclerosis. Atherosclerosis, 2017; 257: 259-265","DOI":"10.1016\/j.atherosclerosis.2016.11.033"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, and Moller DE: The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab, 2013; 18: 333-340","DOI":"10.1016\/j.cmet.2013.08.005"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, Weng Y, Clark R, Lanba A, Owen BM, Brenner MB, Trimmer JK, Gropp KE, Chabot JR, Erion DM, Rolph TP, Goodwin B, and Calle RA: A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab, 2016; 23: 427-440","DOI":"10.1016\/j.cmet.2016.02.001"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, and Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature, 1997; 390: 45-51","DOI":"10.1038\/36285"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, and Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature, 2006; 444: 770-774","DOI":"10.1038\/nature05315"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, and White KE: Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology, 2005; 146: 4647-4656","DOI":"10.1210\/en.2005-0670"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, and Yamashita T: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest, 2004; 113: 561-568","DOI":"10.1172\/JCI19081"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, and Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res, 2004; 19: 429-435","DOI":"10.1359\/JBMR.0301264"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M, and Baum M: FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol, 2009; 297: F282-91","DOI":"10.1152\/ajprenal.90742.2008"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Isakova T, Wahl P, Vargas GS, Guti\u00e9rrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, and Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int, 2011; 79: 1370-1378","DOI":"10.1038\/ki.2011.47"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Yamada S and Nakano T: Role of chronic kidney disease (CKD)-mineral and bone disorder (MBD) in the pathogenesis of cardiovascular disease in CKD. J Atheroscler Thromb, 2023; 30: 835-850","DOI":"10.5551\/jat.RV22006"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Guti\u00e9rrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, J\u00fcppner H, and Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med, 2008; 359: 584-592","DOI":"10.1056\/NEJMoa0706130"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Guti\u00e9rrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, and Wolf M: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA, 2011; 305: 2432-2439","DOI":"10.1001\/jama.2011.826"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, and Shlipak MG: Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol, 2012; 60: 200-207","DOI":"10.1016\/j.jacc.2012.03.040"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Xue C, Yang B, Zhou C, Dai B, Liu Y, Mao Z, Yu S, and Mei C: Fibroblast growth factor 23 predicts all-cause mortality in a dose-response fashion in pre-dialysis patients with chronic kidney disease. Am J Nephrol, 2017; 45: 149-159","DOI":"10.1159\/000454959"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Liu M, Xia P, Tan Z, Song T, Mei K, Wang J, Ma J, Jiang Y, Zhang J, Zhao Y, Yu P, and Liu X: Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis. Front Cardiovasc Med, 2022; 9: 989574","DOI":"10.3389\/fcvm.2022.989574"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Plischke M, Neuhold S, Adlbrecht C, Bielesz B, Shayganfar S, Bieglmayer C, Szekeres T, H\u00f6rl WH, Strunk G, Vavken P, Pacher R, and H\u00fclsmann M: Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Investig, 2012; 42: 649-656","DOI":"10.1111\/j.1365-2362.2011.02631.x"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Ter Maaten JM, Voors AA, Damman K, van der Meer P, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Navis G, Ng L, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, and de Borst MH: Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. Int J Cardiol, 2018; 253: 84-90","DOI":"10.1016\/j.ijcard.2017.10.010"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Andersen IA, Huntley BK, Sandberg SS, Heublein DM, and Burnett Jr JC: Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. Nephrol Dial Transplant, 2016; 31: 767-772","DOI":"10.1093\/ndt\/gfv398"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Mirza MA, Larsson A, Melhus H, Lind L, and Larsson TE: Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis, 2009; 207: 546-551","DOI":"10.1016\/j.atherosclerosis.2009.05.013"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Shibata K, Fujita S, Morita H, Okamoto Y, Sohmiya K, Hoshiga M, and Ishizaka N: Association between circulating fibroblast growth factor 23, \u03b1-klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One, 2013; 8: e73184","DOI":"10.1371\/journal.pone.0073184"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, Lima JA, Polak JF, Blondon M, Ruzinski J, Rock D, and de Boer IH: Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail, 2014; 7: 409-417","DOI":"10.1161\/CIRCHEARTFAILURE.113.000952"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Guti\u00e9rrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, and Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation, 2009; 119: 2545-2552","DOI":"10.1161\/CIRCULATIONAHA.108.844506"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Patel RB, Ning H, de Boer IH, Kestenbaum B, Lima JAC, Mehta R, Allen NB, Shah SJ, and Lloyd-Jones DM: Fibroblast growth factor 23 and long-term cardiac function: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging, 2020; 13: e011925","DOI":"10.1161\/CIRCIMAGING.120.011925"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenst\u00e4dt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, and Faul C: Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab, 2015; 22: 1020-1032","DOI":"10.1016\/j.cmet.2015.09.002"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, Pohl EE, and Erben RG: FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med, 2014; 6: 744-759","DOI":"10.1002\/emmm.201303716"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Weber KT and Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation, 1991; 83: 1849-1865","DOI":"10.1161\/01.CIR.83.6.1849"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Dahl\u00f6f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, and Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002; 359: 995-1003","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Vaidya A and Williams JS: The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism, 2012; 61: 450-458","DOI":"10.1016\/j.metabol.2011.09.007"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Dai B, David V, Martin A, Huang J, Li H, Jiao Y, Gu W, and Quarles LD: A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One, 2012; 7: e44161","DOI":"10.1371\/journal.pone.0044161"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Giachelli CM: Vascular calcification mechanisms. Am Soc Nephrol, 2004; 15: 2959-2964","DOI":"10.1097\/01.ASN.0000145894.57533.C4"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, and Greenland P: Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA, 2010; 303: 1610-1616","DOI":"10.1001\/jama.2010.461"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Hecht HS: Coronary artery calcium scanning: past, present, and future. JACC Cardiovasc Imaging, 2015; 8: 579-596","DOI":"10.1016\/j.jcmg.2015.02.006"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Morita H, Takeda Y, Fujita S, Okamoto Y, Sakane K, Teramoto K, Ozeki M, Tasaki R, Kizawa S, Sohmiya K, Hoshiga M, and Ishizaka N: Gender specific association between serum fibroblast growth factor 23\/\u03b1-klotho and coronary artery and aortic valve calcification. J Atheroscler Thromb, 2015; 22: 1338-1346","DOI":"10.5551\/jat.30635"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Yamada S and Giachelli CM: Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and klotho. Bone, 2017; 100: 87-93","DOI":"10.1016\/j.bone.2016.11.012"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Heiss A, DuChesne A, Denecke B, Gr\u00f6tzinger J, Yamamoto K, Renn\u00e9 T, and Jahnen-Dechent W: Structural basis of calcification inhibition by alpha 2-HS glycoprotein\/fetuin-A: formation of colloidal calciprotein particles. J Biol Chem, 2003; 278: 13333-13341","DOI":"10.1074\/jbc.M210868200"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Kutikhin AG, Feenstra L, Kostyunin AE, Yuzhalin AE, Hillebrands JL, and Krenning G: Calciprotein particles: balancing mineral homeostasis and vascular pathology. Arterioscler Thromb Vasc Biol, 2021; 41: 1607-1624","DOI":"10.1161\/ATVBAHA.120.315697"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Akiyama KI, Miura Y, Hayashi H, Sakata A, Matsumura Y, Kojima M, Tsuchiya K, Nitta K, Shiizaki K, Kurosu H, and Kuro-o M: Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts. Kidney Int, 2020; 97: 702-712","DOI":"10.1016\/j.kint.2019.10.019"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, Rakugi H, and Isaka Y: Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol, 2010; 21: 1998-2007","DOI":"10.1681\/ASN.2009090944"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Chen W, Fitzpatrick J, Monroy-Trujillo JM, Sozio SM, Jaar BG, Estrella MM, Serrano J, Anokhina V, Miller BL, Melamed ML, Bushinsky DA, and Parekh RS: Associations of serum calciprotein particle size and transformation time with arterial calcification, arterial stiffness, and mortality in incident hemodialysis patients. Am J Kidney Dis, 2021; 77: 346-354","DOI":"10.1053\/j.ajkd.2020.05.031"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Aghagolzadeh P, Bachtler M, Bijarnia R, Jackson C, Smith ER, Odermatt A, Radpour R, Pasch A: Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-\u03b1. Atherosclerosis, 2016; 251: 404-414","DOI":"10.1016\/j.atherosclerosis.2016.05.044"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) J\u00e4ger E, Murthy S, Schmidt C, Hahn M, Strobel S, Peters A, St\u00e4ubert C, Sungur P, Venus T, Geisler M, Radusheva V, Raps S, Rothe K, Scholz R, Jung S, Wagner S, Pierer M, Seifert O, Chang W, Estrela-Lopis I, Raulien N, Krohn K, Str\u00e4ter N, Hoeppener S, Sch\u00f6neberg T, Rossol M, and Wagner U: Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis. Nat Commun, 2020; 11: 4243","DOI":"10.1038\/s41467-020-17749-6"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Smith JG, Luk K, Schulz CA, Engert JC, Do R, Hindy G, Rukh G, Dufresne L, Almgren P, Owens DS, Harris TB, Peloso GM, Kerr KF, Wong Q, Smith AV, Budoff MJ, Rotter JI, Cupples LA, Rich S, Kathiresan S, Orho-Melander M, Gudnason V, O\u2019Donnell CJ, Post WS, and Thanassoulis G: Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA, 2014; 312: 1764-1771","DOI":"10.1001\/jama.2014.13959"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, Malhotra R, O\u2019Brien KD, Kamstrup PR, Nordestgaard BG, Tybjaerg-Hansen A, Allison MA, Aspelund T, Criqui MH, Heckbert SR, Hwang SJ, Liu Y, Sjogren M, van der Pals J, K\u00e4lsch H, M\u00fchleisen TW, N\u00f6then MM, Cupples LA, Caslake M, Di Angelantonio E, Danesh J, Rotter JI, Sigurdsson S, Wong Q, Erbel R, Kathiresan S, Melander O, Gudnason V, O\u2019Donnell CJ, and Post WS: Genetic associations with valvular calcification and aortic stenosis. N Engl J Med, 2013; 368: 503-512","DOI":"10.1056\/NEJMoa1109034"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Zhao Y, Nicoll R, He YH, and Henein MY: The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis. Atherosclerosis, 2016; 246: 318-324","DOI":"10.1016\/j.atherosclerosis.2016.01.023"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Linefsky JP, O\u2019Brien KD, Sachs M, Katz R, Eng J, Michos ED, Budoff MJ, de Boer I, and Kestenbaum B: Serum phosphate is associated with aortic valve calcification in the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2014; 233: 331-337","DOI":"10.1016\/j.atherosclerosis.2013.12.051"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) Cheek JD, Wirrig EE, Alfieri CM, James JF, and Yutzey KE: Differential activation of valvulogenic, chondrogenic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease. J Mol Cell Cardiol, 2012; 52: 689-700","DOI":"10.1016\/j.yjmcc.2011.12.013"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116) Wirrig EE, Hinton RB, and Yutzey KE: Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. J Mol Cell Cardiol, 2011; 50: 561-569","DOI":"10.1016\/j.yjmcc.2010.12.005"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117) Gomez-Stallons MV, Wirrig-Schwendeman EE, Hassel KR, Conway SJ, and Yutzey KE: Bone morphogenetic protein signaling is required for aortic valve calcification. Arterioscler Thromb Vasc Biol, 2016; 36: 1398-1405","DOI":"10.1161\/ATVBAHA.116.307526"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118) Vidula MK, Orlenko A, Zhao L, Salvador L, Small AM, Horton E, Cohen JB, Adusumalli S, Denduluri S, Kobayashi T, Hyman M, Fiorilli P, Magro C, Singh B, Pourmussa B, Greczylo C, Basso M, Ebert C, Yarde M, Li Z, Cvijic ME, Wang Z, Walsh A, Maranville J, Kick E, Luettgen J, Adam L, Schafer P, Ramirez-Valle F, Seiffert D, Moore JH, Gordon D, and Chirinos JA: Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis. Eur J Heart Fail, 2021; 23: 2021-2032","DOI":"10.1002\/ejhf.2361"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119) Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, and White KE: Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology, 2005; 146: 4647-4656","DOI":"10.1210\/en.2005-0670"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120) Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, and Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001; 285: 2370-2375","DOI":"10.1001\/jama.285.18.2370"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121) Mathew JS, Sachs MC, Katz R, Patton KK, Heckbert SR, Hoofnagle AN, Alonso A, Chonchol M, Deo R, Ix JH, Siscovick DS, Kestenbaum B, and de Boer IH: Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation, 2014; 130: 298-307","DOI":"10.1161\/CIRCULATIONAHA.113.005499"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122) Mehta R, Cai X, Lee J, Scialla JJ, Bansal N, Sondheimer JH, Chen J, Hamm LL, Ricardo AC, Navaneethan SD, Deo R, Rahman M, Feldman HI, Go AS, Isakova T, and Wolf M: Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. JAMA Cardio, 2016; 1: 548-556","DOI":"10.1001\/jamacardio.2016.1445"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123) Alonso A, Misialek JR, Eckfeldt JH, Selvin E, Coresh J, Chen LY, Soliman EZ, Agarwal SK, and Lutsey PL: Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. J Am Heart Assoc, 2014; 3: e001082","DOI":"10.1161\/JAHA.114.001082"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124) Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Guti\u00e9rrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-o M, Kusek JW, Keane MG, and Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest, 2011; 121: 4393-4408","DOI":"10.1172\/JCI46122"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125) Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, and Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res, 2004; 19: 429-435","DOI":"10.1359\/JBMR.0301264"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126) D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, and Wolf M: Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol, 2012; 7: 1155-1162","DOI":"10.2215\/CJN.13281211"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127) Mirza MA, Larsson A, Lind L, and Larsson TE: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis, 2009; 205: 385-390","DOI":"10.1016\/j.atherosclerosis.2009.01.001"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128) Malyszko J, Koc-Zorawska E, Matuszkiewicz-Rowinska J, and Malyszko J: FGF23 and Klotho in relation to markers of endothelial dysfunction in kidney transplant recipients. Transplant Proc, 2014; 46: 2647-2650","DOI":"10.1016\/j.transproceed.2014.09.015"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129) Natsuki Y, Morioka T, Kakutani Y, Yamazaki Y, Ochi A, Kurajoh M, Mori K, Imanishi Y, Shoji T, Inaba M, and Emoto M: Serum fibroblast growth factor 23 levels are associated with vascular smooth muscle dysfunction in type 2 diabetes. J Atheroscler Thromb, 2023; 30: 1838-1848","DOI":"10.5551\/jat.64000"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130) Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, and Solomon SD: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA, 2012; 307: 674-684","DOI":"10.1001\/jama.2012.120"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131) Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, and Thadhani R: Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J, 2012; 164: 902-9.e2","DOI":"10.1016\/j.ahj.2012.09.018"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132) Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, and Goldsmith D: Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant, 2009; 24: 1506-1523","DOI":"10.1093\/ndt\/gfn613"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133) Lioufas NM, Pascoe EM, Hawley CM, Elder GJ, Badve SV, Block GA, Johnson DW, and Toussaint ND: Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol, 2022; 33: 59-76","DOI":"10.1681\/ASN.2021040554"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134) Isaka Y, Hamano T, Fujii H, Tsujimoto Y, Koiwa F, Sakaguchi Y, Tanaka R, Tomiyama N, Tatsugami F, and Teramukai S: Optimal phosphate control related to coronary artery calcification in dialysis patients. J Am Soc Nephrol, 202; 32: 723-735","DOI":"10.1681\/ASN.2020050598"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/11\/31_RV22025\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T04:40:29Z","timestamp":1730522429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/11\/31_RV22025\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":134,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv22025","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"article-number":"RV22025"}}